Precigen, Inc. Hits New 52-Week High of $7.71, Up 336%

Precigen, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 7.71 on August 26, 2026. This achievement marks a remarkable 336.47% increase in the company's stock price over the past year, significantly outperforming the S&P 500, which has seen a gain of 18.71% during the same period. With a market capitalization of USD 1,299 million, Precigen operates in a competitive industry characterized by rapid innovation and development. Despite its recent stock performance, the company remains in a loss-making position, as indicated by its negative price-to-earnings ratio and a return on equity of -512.71%. Additionally, Precigen has a price-to-book ratio of 62.12, reflecting its valuation relative to its assets. As the company continues to navigate the dynamic landscape of pharmaceuticals and biotechnology, this new high underscores its recent performance trajectory and market positioning.